Sign In
BIVV.US
id: 663

Bioverativ (BIVV) $84M Shareholder Settlement

Delaware court of Chancery
Court
2020-1061
Case number
24 May 2017
Class period Start
08 Mar 2018
Class period End
This settlement of $84 million resolves claims over the acquisition of Bioverativ by Sanofi, whereby $BIVV stockholders received $105 in cash for each.

Who is eligible to get a payout?

All persons who held outstanding shares of Bioverativ common stock, either of record or beneficially, at any time during the between May 24, 2017 and March 8, 2018.

Do you need to sell your securities to be eligible?

No, if you have purchased them within the class period, you are eligible to participate.

How long does the payout process take?

The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Shareholder
Investment Bank
Service Provider
Security Type
Stocks
Trade Direction
Long
Payout per Share
7.6
Filing date
07 March 2018
Plaintiffs
Stewart N. Goldstein, M.D.
Attorneys
Prickett, Jones & Elliott, P.A., Cooch & Taylor P.A., Robbins Geller Rudman & Dowd LLP, Johnson Fistel LLP
Defendants
John G. Cox, Anna Protopapas, Brian S. Posner, Louis J. Paglia, Geno J. Germano, John T. Greene, Andrea DiFabio, Alexander J. Denner
Judge
Judge Phillips
Administrator
Gilardi & Co LLC
Settlement agreement date
2023-03-12
Trades matching type
FIFO
+$84,000,000
Total Settlement Amount

Bioverativ Inc

Bioverativ Inc., a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United...

    Ticker
    BIVV.US
    ISIN
    US09075E1001
    CIK
    1681689
    Sector
    Other
    Industry
    Other
    Country
    USA
    Address
    225 Second Avenue 02451,Waltham,USA